Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SERPASIL-APRESOLINE vs ALDORIL D50
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of reserpine (depletes catecholamines from sympathetic nerve endings) and hydralazine (direct vasodilator, increases c GMP via NO).
Aldoril D50 is a combination of methyldopa and hydrochlorothiazide. Methyldopa is a centrally-acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume and further lowering blood pressure.
Hypertension
Hypertension (first-line or second-line therapy),Hypertensive urgency (off-label)
1 tablet (containing reserpine 0.1 mg and hydralazine 25 mg) orally once daily; may increase to twice daily if needed. Maximum dose: 2 tablets per day.
1 tablet (hydrochlorothiazide 25 mg + methyldopa 250 mg) orally twice daily; maximum dose: 2 tablets (50 mg + 500 mg) twice daily.
Reserpine: ~50-100 hours (biphasic; terminal phase 4.5-11 days due to enterohepatic circulation and tissue binding). Hydralazine: 2-8 hours (rapid acetylators 30-50 min, slow acetylators 2-8 hours); longer in renal impairment.
3–6 hours (terminal elimination half-life); clinical context: requires twice-daily dosing for sustained blood pressure control; prolonged in renal impairment.
Reserpine: hydrolyzed in gut, metabolites excreted in urine. Hydralazine: N-acetylation via NAT2.
Methyldopa is extensively metabolized in the liver via conjugation and O-methylation, with involvement of catechol-O-methyltransferase (COMT). Hydrochlorothiazide is not extensively metabolized; it is eliminated largely unchanged by the kidneys.
Reserpine: <1% unchanged in urine; extensive hepatic metabolism followed by renal and fecal excretion. Hydralazine: 80-90% renal; 10% fecal; 1-2% unchanged in urine; polymorphic acetylation (rapid/slow acetylators) affects clearance.
Renal: 50% as unchanged drug and 20% as metabolites; biliary/fecal: ~25% (as metabolites); total renal clearance accounts for ~70% of elimination.
Reserpine: ~96% (bound to albumin and α1-acid glycoprotein). Hydralazine: 85-90% (primarily albumin; also binds to α1-acid glycoprotein and lipoproteins).
~20% bound to albumin; minimal binding to other plasma proteins.
Reserpine: ~8-10 L/kg (extensive tissue binding, especially adipose and brain). Hydralazine: 1.5-8 L/kg (increases with hypertension; reflects high tissue distribution).
0.2–0.3 L/kg (moderately low Vd, indicating limited extravascular distribution and predominantly plasma water distribution).
Reserpine: 5-30% oral (extensive first-pass metabolism; variable). Hydralazine: 30-50% oral (slow acetylators have higher bioavailability due to reduced first-pass acetylation; rapid acetylators 10-30%).
Oral: 30–40% (due to extensive first-pass metabolism); IV: 100%.
GFR <30 m L/min: Use with caution; reduce hydralazine component by 50%. GFR 30-50 m L/min: No adjustment needed for hydralazine; reserpine use contraindicated if severe renal impairment.
Contraindicated if GFR < 30 m L/min; for GFR 30-50 m L/min: reduce dose and monitor electrolytes.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce hydralazine dose by 50%. Child-Pugh C: Contraindicated due to risk of encephalopathy from reserpine and hepatotoxicity.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50% and monitor; Class C: contraindicated.
Weight-based: 0.01 mg/kg reserpine and 2.5 mg/kg hydralazine per day orally, divided into 1-2 doses. Maximum: reserpine 0.25 mg/day, hydralazine 50 mg/day.
Not recommended; inadequate safety data.
Start at half the adult dose (1 tablet every other day) due to increased sensitivity to hypotension and CNS depression. Monitor for orthostatic hypotension and electrolyte imbalances.
Start with 1 tablet (hydrochlorothiazide 12.5 mg + methyldopa 125 mg) once daily; increase slowly; monitor for hypotension and electrolyte imbalance.
None
None
Reserpine may cause depression, peptic ulcer, or arrhythmias.,Hydralazine may cause drug-induced lupus, peripheral neuritis, or orthostatic hypotension.,Monitor for hypotension and renal impairment.
Sedation and drowsiness common; avoid driving or hazardous activities. Risk of Coombs-positive hemolytic anemia with methyldopa (discontinue if anemia develops). Hepatotoxicity and liver function abnormalities (discontinue if jaundice occurs). Orthostatic hypotension; caution in volume-depleted patients. Electrolyte imbalances (particularly hypokalemia, hyponatremia) with hydrochlorothiazide; monitor serum electrolytes. Sulfonamide cross-sensitivity possible. Exacerbation of systemic lupus erythematosus. Avoid abrupt withdrawal of methyldopa (may cause rebound hypertension).
Hypersensitivity to reserpine or hydralazine,Active peptic ulcer,Ulcerative colitis,Depression, especially with suicidal tendencies,Coronary artery disease (hydralazine may cause tachycardia)
Active hepatic disease (cirrhosis, hepatitis) associated with methyldopa therapy; previous methyldopa-induced liver disorders. Anuria or hypersensitivity to thiazide diuretics or sulfonamide-derived drugs. Concomitant use with MAO inhibitors. Severe renal impairment (creatinine clearance <30 m L/min) or electrolyte depletion due to hydrochlorothiazide. Concurrent lithium therapy (risk of lithium toxicity).
Avoid tyramine-rich foods (aged cheeses, cured meats, fermented products, soy sauce, beer, wine) due to MAO inhibition from reserpine component; however, risk is lower than classical MAOIs. Avoid alcohol. Limit foods high in sodium to prevent fluid retention.
Avoid potassium supplements or salt substitutes containing potassium without consulting doctor. Limit alcohol intake. Avoid excessive grapefruit juice. Maintain adequate potassium intake through diet to prevent hypokalemia.
First trimester: Limited data; beta-blockers (reserpine component) associated with fetal bradycardia and growth restriction. Second/third trimester: Hydralazine and reserpine may cause neonatal hypotension, bradycardia, and hypothermia. Reserpine may increase risk of neonatal respiratory depression and nasal congestion.
Hydrochlorothiazide (HCTZ) is Pregnancy Category B in first trimester and Category D in second/third trimesters. Methyldopa (M) is Category B. HCTZ use in second/third trimester may cause fetal/neonatal effects including electrolyte disturbances, jaundice, thrombocytopenia, and possible fetal growth restriction. Methyldopa has not shown teratogenicity. Aldoril D50 (M 500mg/HCTZ 50mg) is not recommended during pregnancy, especially after first trimester.
Reserpine and hydralazine are excreted in breast milk. M/P ratio not well established. Reserpine may cause adverse effects in infants (diarrhea, nasal congestion). Hydralazine is considered compatible with caution. Avoid or use alternative antihypertensives with more safety data.
Both methyldopa and HCTZ are excreted in breast milk. Methyldopa M/P ratio approximately 1.0; HCTZ M/P ratio variable, small amounts. Use during breastfeeding may suppress lactation due to HCTZ diuretic effect. Monitor infant for signs of hypotension, electrolyte imbalance. Caution recommended; use only if clearly needed.
Pregnancy may alter pharmacokinetics of hydralazine (increased clearance) and reserpine (limited data). Dose adjustments may be needed based on blood pressure response. Avoid use in pregnancy if possible; no standard recommended dose adjustments.
Pregnancy-induced increase in plasma volume may reduce effectiveness of HCTZ, requiring dose adjustment. Methyldopa pharmacokinetics not significantly altered; however, increased clearance in pregnancy may require higher doses. In preeclampsia, dose adjustments may be needed. Avoid HCTZ in pregnancy if possible.
Serpasil-Apresoline is a fixed-dose combination of reserpine and hydralazine, both antihypertensives with complementary mechanisms. Reserpine depletes catecholamines and serotonin, while hydralazine is a direct vasodilator. This combination is rarely used today due to poor tolerability (significant CNS depression, depression risk) and availability of better-tolerated agents. Monitor for orthostatic hypotension, bradycardia, and signs of depression. Avoid in patients with history of depression, peptic ulcer disease, or MAOI use. Abrupt withdrawal can cause hypertensive crisis.
ALDORIL D50 combines methyldopa and hydrochlorothiazide. Monitor for orthostatic hypotension, especially in volume-depleted patients. May cause positive Coombs test, hemolytic anemia, and lupus-like syndrome. Avoid in pheochromocytoma. Use caution in hepatic disease.
Take exactly as prescribed; do not skip doses or stop suddenly.,May cause dizziness or lightheadedness; rise slowly from sitting or lying positions.,Avoid alcohol and other central nervous system depressants.,Report any persistent fatigue, mood changes, or signs of depression.,May cause nasal congestion; do not use decongestants without consulting doctor.,Avoid prolonged sun exposure; may increase skin photosensitivity.,Contact doctor if you experience swelling of ankles/feet, weight gain, or shortness of breath.,Store at room temperature away from moisture and light.
Take exactly as prescribed; do not skip doses or double up.,May cause dizziness or drowsiness; avoid driving until you know how it affects you.,Report unexplained fever, jaundice, or dark urine immediately.,Avoid sudden discontinuation; may cause rapid increase in blood pressure.,Stay hydrated but do not overhydrate; monitor for signs of electrolyte imbalance.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SERPASIL-APRESOLINE vs ALDORIL D50, answered by our medical review team.
SERPASIL-APRESOLINE is a Antihypertensive Combination that works by Combination of reserpine (depletes catecholamines from sympathetic nerve endings) and hydralazine (direct vasodilator, increases c GMP via NO).. ALDORIL D50 is a Antihypertensive Combination that works by Aldoril D50 is a combination of methyldopa and hydrochlorothiazide. Methyldopa is a centrally-acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume and further lowering blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SERPASIL-APRESOLINE and ALDORIL D50 depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SERPASIL-APRESOLINE is: 1 tablet (containing reserpine 0.1 mg and hydralazine 25 mg) orally once daily; may increase to twice daily if needed. Maximum dose: 2 tablets per day.. The standard adult dose of ALDORIL D50 is: 1 tablet (hydrochlorothiazide 25 mg + methyldopa 250 mg) orally twice daily; maximum dose: 2 tablets (50 mg + 500 mg) twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SERPASIL-APRESOLINE and ALDORIL D50 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SERPASIL-APRESOLINE is classified as Category C. First trimester: Limited data; beta-blockers (reserpine component) associated with fetal bradycardia and growth restriction. Second/third trimester: Hydralazine and reserpine may c. ALDORIL D50 is classified as Category C. Hydrochlorothiazide (HCTZ) is Pregnancy Category B in first trimester and Category D in second/third trimesters. Methyldopa (M) is Category B. HCTZ use in second/third trimester ma. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.